Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

Lucentis picture

NICE rejects Lucentis in diabetic macular oedema

November 29, 2011
Sales and Marketing Lucentis, NICE

NICE has rejected Novartis’ Lucentis for diabetic macular oedema. NICE has not recommended Lucentis (ranibizumab) for the treatment of diabetic …

News
NICE hq pic

NICE okays Eliquis for blood clots after surgery

November 25, 2011
Research and Development, Sales and Marketing BMS, Eliquis, NICE, Pfizer

NICE is recommending Pfizer and Bristol-Myers Squibb’s Eliquis for blood clots after surgery. Specifically, NICE has said that Eliquis (apixaban) …

News

NICE confirms ‘no’ for colorectal cancer drugs

November 24, 2011
Sales and Marketing Erbitux, NICE, Vectibix, avastin, colorectal cancer

 

News
Lucentis image

Lucentis not backed by NICE for new licence

November 24, 2011
Sales and Marketing Lucentis, NICE, Novartis, Ozurdex

NICE has not recommended Novartis’ eye disease drug Lucentis due to ‘gaps and uncertainties’ in the manufacturer’s submission. In draft …

News
screen_shot_2011-11-24_at_09

Professor Sir Michael Rawlins reappointed as NICE chairman

November 24, 2011
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Rawlins

The National Institute for Health and Clinical Excellence (NICE) has reappointed Professor Sir Michael Rawlins as NICE chairman for a …

Appointment

NICE will not back Eisai’s Halaven

November 17, 2011
Medical Communications, Sales and Marketing Eisai, Halaven, NICE, breast cancer

NICE has not recommended Eisai’s novel breast cancer drug Halaven due to concerns over its safety and cost.In draft guidance …

News

NICE won’t back Faslodex in breast cancer

November 10, 2011
Sales and Marketing AstraZeneca, Faslodex, NICE

NICE has not recommended AstraZeneca’s breast cancer drug Faslodex as it says the drug is no better than existing treatments. …

News
Tyverb

Cancer drugs should not receive special funding – MS Society

November 4, 2011
Sales and Marketing ABPI, Cancer Drugs Fund, MS Society, NICE

 

News
Pradaxa

NICE U-turn on Boehringer’s Pradaxa

November 1, 2011
Sales and Marketing NICE, Pradaxa

NICE is now recommending Boehringer Ingelheim’s Pradaxa for stroke prevention after initially rejecting the drug on cost-effectiveness issues. NICE has …

News

Brilique gains NICE approval

October 31, 2011
Sales and Marketing ACS, Brilique, NICE, Plavix, clopidogrel

AstraZeneca’s Brilique has been approved by NICE for use in combination with aspirin as an option to treat patients with …

News
NICE building

Mepact wins NICE backing

October 26, 2011
Research and Development, Sales and Marketing Mepact, NICE

NICE has recommended Takeda’s bone cancer drug Mepact after the firm offered a discount for the treatment. The watchdog’s final …

News
Byetta

NICE recommends Lilly’s long-acting Bydureon

October 18, 2011
Sales and Marketing Bydureon, NICE, diabetes

NICE has recommended Eli Lilly’s long-acting diabetes drug Bydureon after the failure of oral treatments. Bydureon (exenatide) – a long-acting …

News
Yervoy

NICE: Bristol-Myers Squibb’s Yervoy too costly

October 14, 2011
Sales and Marketing NICE, Yervoy

Bristol Myers Squibb has failed to win NICE backing for its melanoma drug Yervoy after the Institute judged its £80,000 …

News

NICE recommends RoActemra for early use in arthritis

October 13, 2011
Sales and Marketing NICE, RoActemra

NICE has recommended Roche’s drug RoActemra be used at an earlier stage for some arthritis patients. In draft guidance NICE …

News
GSK

NICE says no to lupus treatment

September 30, 2011
Sales and Marketing Benylsta, GSK, Lupus, NICE

NICE has rejected GSK’s new lupus treatment Benlysta in draft guidance.Co-developed with biotech company HGS, the drug has been hailed …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026